Viatris Appoints David Simmons to Board of Directors, Boosting Pharmaceutical Expertise

Viatris has appointed David Simmons to its Board of Directors, bringing extensive pharmaceutical industry expertise and experience in global sales and operations. Simmons previously led PPD, Inc. and managed a workforce of over 30,000 employees, and was instrumental in the company's $17.4 billion acquisition by Thermo Fisher Scientific. His background at Pfizer and board experience will bolster Viatris' growth and shareholder value.

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, has announced the appointment of David Simmons to its Board of Directors. The addition of Simmons, who brings extensive pharmaceutical industry experience and a proven track record in global sales and operations, underscores Viatris' commitment to strategic growth and shareholder value.

Simmons, who currently serves as CEO of Caliber Holdings Corporation, has a distinguished career spanning over three decades in the pharmaceutical industry. Prior to his current role, he served as Operating Partner of Hellman & Friedman, LLC, a leading private equity firm, and held executive positions at Pfizer Inc. and PPD, Inc. [1]

At PPD, Simmons led a global workforce of over 30,000 employees across 46 countries, overseeing drug development programs for pharmaceutical customers. Under his leadership, PPD's total enterprise value more than tripled, and he successfully guided the company through its 2020 IPO and subsequent acquisition by Thermo Fisher Scientific Inc. for $17.4 billion in 2021. [1]

His experience at Pfizer, where he rose to become the first President and General Manager of the Established Products Unit and later added responsibilities for Emerging Markets and Established Products, further highlights his expertise in managing large-scale operations and achieving significant sales growth. [1]

Simmons' appointment to Viatris' Board of Directors comes at a critical juncture for the company, which is uniquely positioned to bridge the divide between generics and brands. His background in drug development and capital markets, coupled with his familiarity with Viatris' established products portfolio, aligns perfectly with the company's strategic goals. [1]

Melina Higgins, Chair of Viatris' Board of Directors, expressed her satisfaction with Simmons' appointment, noting his extensive executive, industry, and board expertise. Scott A. Smith, Viatris' Chief Executive Officer, also welcomed Simmons, highlighting his ability to contribute as both a strategist and an executor. [1]

This strategic move by Viatris is expected to bolster the company's efforts in advancing its pipeline and preparing for future growth opportunities. As the global healthcare landscape continues to evolve, with a growing focus on biologics and biosimilars, Viatris' appointment of David Simmons positions it well to capitalize on these trends. [2]

References:
[1] https://www.biospace.com/press-releases/viatris-announces-appointment-of-david-simmons-to-the-companys-board-of-directors
[2] https://finance.yahoo.com/news/cell-line-development-market-outlook-163000931.html